On Apr. 30, 2020, Mateon Therapeutics reported several peer-reviewed publications derived from its R&D effort against COVID-19. Published Apr. 24, is a special report in the biomedical journal Annals of Pulmonary and Critical Care Medicine regarding the medical-scientific rationale for its planned randomized, placebo-controlled, Phase 2 Study of OT-101 in COVID-19 patients with hypoxemic respiratory failure.